PDS Biotech Shares Data Update From Ongoing VERSATILE-002 Phase 2 Clinical Trial In Head and Neck Cancer
Portfolio Pulse from Benzinga Newsdesk
PDS Biotechnology Corporation (NASDAQ:PDSB) provided an update on its ongoing VERSATILE-002 Phase 2 clinical trial for head and neck cancer. The trial shows a median overall survival of 30 months, with some patients approaching 3 years of survival.
June 12, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PDS Biotechnology Corporation provided an update on its VERSATILE-002 Phase 2 trial, showing promising survival data for head and neck cancer patients.
The positive data from the VERSATILE-002 trial is likely to boost investor confidence in PDS Biotech's pipeline, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100